Cardiac biomarker testing market outlook in Latin America Thu, 10th Nov 2022 Article tags In-vitro diagnosticsPoint-of-care testing (POCT)AmericasIVD GatewayPoint-of-care testing (POCT) The incidence of cardiovascular diseases (CVD) in Latin America (LATAM) is increasing and so is the demand for cardiac biomarker testing. Four conditions associated with acute coronary syndrome: heart attack, heart failure, atrial fibrillation and hypertension affect almost 30% of the adult population in the region. Cardiac biomarkers play an increasingly important role in supporting timely, accurate diagnosis and management of acute coronary syndrome to prevent death. The market size of cardiac immunoassays used in central laboratories is expected to grow in the range of 1.5 to 10.7 on an annual average from 2021 to 2026 in key LATAM markets. Point-of-care (POC) solutions are challenging the dominance of lab-based tests to risk stratify and diagnose patients—especially in emergency settings, with an average 2021-2026 annual growth ranging from 2.4 to 10.9% across key LATAM markets. What are cardiac biomarker tests?Cardiac biomarker testing is a diagnostic cornerstone for acute coronary syndromes (ACS) such as myocardial infarction (MI)—or heart attacks—which are a common reason for emergency department (ED) visits. Commonly used cardiac biomarkers in testing include troponin, BNP, proBNP, myoglobin, and creatine kinase myoglobin (CK-MB).Cardiac biomarker testing can be done at central laboratories or at the point-of-care (POC) in different clinical settings such as acute care settings: operating rooms, intensive care unit and ED. POC cardiac tests and devices help to improve turnaround time for reporting results of cardiac markers, supporting timely treatment and medical intervention of emergency CVD cases. Essential 2021-2026 insights on the LATAM cardiac biomarker test market : The demand for cardiac testing is growing fastest in countries such as Argentina and Chile. Most cardiac testing takes place at central laboratories, given the cheaper cost of testing with cardiac immunoassays compared to POC tests. In most LATAM countries, the market size of cardiac immunoassays used in central laboratories is several times larger than POC cardiac tests. The POC cardiac test market is expected to grow strongly in LATAM markets such as Chile, Peru, Argentina. In these countries, the POC cardiac test market is expected to grow at more than 7% on an annual average from 2021 to 2026.The POC cardiac test market is growing faster than lab-based cardiac testing in many LATAM countries such as Brazil, Colombia, Chile and Peru. IVD GatewayThe go-to source for tracking and understanding market size, share and trends in IVD. Granular break-out of data and comprehensive coverage of international and domestic suppliers’ brand share across Asia, Europe, Latin America and the Middle East. Find out more Clearstate newsletterSign up to our newsletter for insights into key market data, trends and developments across IVD and Surgical segments from our specialists and analysts. Sign up now Thu, 10th Nov 2022 Article tags In-vitro diagnosticsPoint-of-care testing (POCT)AmericasIVD GatewayPoint-of-care testing (POCT)
What are cardiac biomarker tests?Cardiac biomarker testing is a diagnostic cornerstone for acute coronary syndromes (ACS) such as myocardial infarction (MI)—or heart attacks—which are a common reason for emergency department (ED) visits. Commonly used cardiac biomarkers in testing include troponin, BNP, proBNP, myoglobin, and creatine kinase myoglobin (CK-MB).Cardiac biomarker testing can be done at central laboratories or at the point-of-care (POC) in different clinical settings such as acute care settings: operating rooms, intensive care unit and ED. POC cardiac tests and devices help to improve turnaround time for reporting results of cardiac markers, supporting timely treatment and medical intervention of emergency CVD cases.
IVD GatewayThe go-to source for tracking and understanding market size, share and trends in IVD. Granular break-out of data and comprehensive coverage of international and domestic suppliers’ brand share across Asia, Europe, Latin America and the Middle East. Find out more
Clearstate newsletterSign up to our newsletter for insights into key market data, trends and developments across IVD and Surgical segments from our specialists and analysts. Sign up now